Repository logo
 

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.

Simple item page
cam.issuedOnline2011-07-31
dc.contributor.authorCorazzelli, Gaetano
dc.contributor.authorFrigeri, Ferdinando
dc.contributor.authorArcamone, Manuela
dc.contributor.authorAloj, Luigi
dc.contributor.authorCapobianco, Gaetana
dc.contributor.authorBecchimanzi, Cristina
dc.contributor.authorMorelli, Emanuela
dc.contributor.authorVolzone, Francesco
dc.contributor.authorMarcacci, Gianpaolo
dc.contributor.authorRusso, Filippo
dc.contributor.authorDe Filippi, Rosaria
dc.contributor.authorLastoria, Secondo
dc.contributor.authorPinto, Antonio
dc.contributor.orcidAloj, Luigi [0000-0002-7452-4961]
dc.date.accessioned2018-12-22T00:31:48Z
dc.date.available2018-12-22T00:31:48Z
dc.date.issued2011-12
dc.description.abstractPatients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120 mg/m(2) every 21 d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+ d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.
dc.format.mediumPrint-Electronic
dc.identifier.doi10.17863/CAM.34721
dc.identifier.eissn1600-0609
dc.identifier.issn0902-4441
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/287417
dc.languageeng
dc.language.isoeng
dc.publisherWiley
dc.publisher.urlhttp://dx.doi.org/10.1111/j.1600-0609.2011.01683.x
dc.rightsPublisher's own licence
dc.subjectAged
dc.subjectAntineoplastic Agents, Alkylating
dc.subjectHumans
dc.subjectLymphoma, T-Cell
dc.subjectMiddle Aged
dc.subjectNitrosourea Compounds
dc.subjectOrganophosphorus Compounds
dc.titleEfficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
dc.typeArticle
prism.endingPage553
prism.issueIdentifier6
prism.publicationDate2011
prism.publicationNameEur J Haematol
prism.startingPage547
prism.volume87
rioxxterms.licenseref.startdate2011-12
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1111/j.1600-0609.2011.01683.x

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.pdf
Size:
147.76 KB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DepositLicenceAgreementv2.1.pdf
Size:
150.9 KB
Format:
Adobe Portable Document Format
Download

Collections

Cambridge University Research Outputs